In short
Clinical trials are investigating Apocynin in people with knee osteoarthritis. The main goal is to see whether it can help reduce knee pain and how well it works compared with placebo and standard treatment. One completed phase 2 study tested a combination treatment in adults with this condition.
Key points
- Clinical trials of Apocynin in the provided data focus on knee osteoarthritis. The completed study was a Phase 2, placebo-controlled, double-blinded, randomized, dose-finding trial. It tested APPA, a combination that includes Apocynin, against placebo and a standard treatment. The trial enrolled 225 adults with knee osteoarthritis. The main outcome was change in knee pain at week 12 using the WOMAC pain score.
Trial overview
The available clinical trial data for Apocynin describe one completed study in people with knee osteoarthritis.
This was a Phase 2 trial, which means the study was mainly looking at whether the treatment may help and also gathering more information about the treatment in a patient group.
Study design and treatments
The trial was placebo-controlled, double-blinded, and randomized.
In simple terms, participants were assigned by chance to a treatment group, and neither the participants nor the study team knew which treatment was given during the study.
The study also used a dose-finding approach, meaning it was designed to explore the treatment amount being tested.
The treatments compared were APPA, a matching placebo, and Panodil film-coated tablets 500 mg in a new formulation.
APPA was given orally at 2400 mg in the trial.
Who participated
The study enrolled 225 participants.
The target population was adults with knee osteoarthritis.
What the trial measured
The primary endpoint was the change from the start of the study in the WOMAC pain sub-score for the target knee at week 12.
The WOMAC pain sub-score is a standard questionnaire score used to measure pain in osteoarthritis.
The brief study summary says the trial aimed to evaluate the change in pain of the target knee.
What these results mean for patients
This trial was designed to see whether a treatment containing Apocynin could improve knee pain in people with osteoarthritis.
Because the study is listed as completed, the main focus of the available data is the study design and the outcome it planned to measure, not a full set of published results.
For patients, the most important point is that the research centered on pain relief in one specific knee over a 12-week period.